CSA Medical Gains New CPT Code Milestone for Bronchial Cryotherapy as RejuvenAir PMA Under FDA Review

CSA Medical Inc has shared an update.

The company reported that the American Medical Association has released a new CPT® Category III code (1040T) for flexible bronchoscopy with bronchial cryotherapy, effective July 1, 2026. CSA Medical indicated that this coding milestone represents an initial step toward reimbursement and coverage for Metered CryoSpray therapy targeting chronic bronchitis. The company also noted that the Premarket Approval (PMA) application for its RejuvenAir® System is currently under review by the U.S. Food and Drug Administration (FDA).

For investors, the creation of a dedicated Category III CPT code is significant as it formally recognizes the procedure within the U.S. reimbursement framework, even though Category III codes do not yet guarantee widespread payment. If the RejuvenAir System secures FDA approval and payers begin to adopt reimbursement tied to code 1040T, CSA Medical could see a clearer pathway to commercialization and revenue generation in the chronic bronchitis and broader COPD treatment market. This development may enhance the company’s competitive position in interventional pulmonology by lowering future adoption barriers for providers who require coding and reimbursement mechanisms to integrate new procedures into clinical practice. However, revenue impact remains contingent on successful FDA approval, subsequent conversion to permanent (Category I) coding over time, and payer coverage decisions, all of which introduce regulatory and market-access risk that investors should monitor closely.